3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Colorectal Neoplasms
5
Biliary Tract Neoplasms
4
Colonic Neoplasms
3
Sarcoma
2
Rectal Neoplasms
2
Nasopharyngeal Carcinoma
2
Gastrointestinal Stromal Tumors
2
Uterine Cervical Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Rare Tumour
1
Piebaldism
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Multiple Primary
1
Neoplasm Metastasis
1
NSCLC
1
Meningeal Carcinomatosis
1
Lung Neoplasms
1
Histiocytoma, Malignant Fibrous
1
HER2-positive Breast Cancer
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Dermatofibrosarcoma
1
Interventions
Imatinib Mesylate
4
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
saracatinib
1
pembrolizumab
1
pazopanib
1
envafolimab
1
TTI-621
1
Sunitinib
1
Razoxane
1
Radiotherapy, Intensity-Modulated
1
Radiation Dose Hypofractionation
1
Quality of Life
1
Polymerase Chain Reaction
1
Neoadjuvant Therapy
1
MLN 8237
1
Ipilimumab
1
Gene Expression Profiling
1
Dexrazoxane
1
Dactinomycin
1
Blotting, Western
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Dermatofibrosarcoma
×
envafolimab
×
Clear all
NCT04480502
2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2
Active not recruiting
207 enrolled